Tourette Syndrome (Pediatric)
TEVATeva Pharmaceutical Industries LtdCatalyst overview
Research summary
This catalyst tracks a PDUFA approval decision for Ecopipam (D1 Receptor Antagonist) in Tourette Syndrome (Pediatric). The expected timing is based on the latest available company guidance and may change.
04/29/26:- Ecopipam completed Phase 3 for pediatric Tourette syndrome; NDA-ready program added via Emalex acquisition. 06/18/26:- NDA submitted to FDA for pediatric Tourette syndrome; Phase 3 data published in JAMA Neurology. 08/19/26:- FDA accepted ecopipam NDA; D1AMOND trials support. PDUFA action date is Late Q1 2027.
Verification
Confirm timing and program details against the company announcement or filing.